AMAG Pharmaceuticals, Inc. ‘s AMAG shares were up 7.8% after the company announced that it has initiated start up activities for a head to head phase III study to evaluate Feraheme in comparison with Injectafer in adults with iron
AMAG to Initiate Head-to-Head Phase III Study on Feraheme
